Three Cases of Advanced Melanoma With Severe irAE Colitis With Rapid Tumor Progression Following Infliximab Administration
- 28 October 2025
- journal article
- Published by Wiley in The Journal of Dermatology
- Vol. 53 (1) , 140-144
Abstract
Immune checkpoint inhibitors (ICIs) have improved melanoma outcomes but can cause severe immune‐related colitis. Infliximab is often used for steroid‐refractory cases, yet its effect on tumor control remains uncertain. We describe three advanced melanoma patients who developed grade 3–4 colitis after nivolumab plus ipilimumab and were treated with infliximab. Although gastrointestinal symptoms improved, all showed rapid disease progression and died within 3–9 months. These cases suggest that infliximab may compromise antitumor immunity in melanoma patients receiving ICIs.Keywords
This publication has 12 references indexed in Scilit:
- CMV IgG in the blood is not associated with hepatitis but correlates with poor outcomes in immunotherapy treated melanoma patientsCancer Immunology, Immunotherapy, 2025
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2025
- Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical TrialsJournal of Clinical Oncology, 2024
- Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanomaEuropean Journal of Cancer, 2024
- Infliximab for Treatment of Immune Adverse Events and Its Impact on Tumor ResponseCancers, 2023
- LL-37 Might Promote Local Invasion of Melanoma by Activating Melanoma Cells and Tumor-Associated MacrophagesCancers, 2023
- Efficacy comparison between anti-PD-1 antibody monotherapy and anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy for advanced acral melanoma: A retrospective, multicenter study of 254 Japanese patientsEuropean Journal of Cancer, 2022
- Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)ESMO Open, 2021
- Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment RegistryClinical Cancer Research, 2020
- Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or PlaceboJAMA Oncology, 2020